Qomatropin

Human Growth Hormone, also referred to as Somatropin, is a polypeptide hormone that is synthesized by the anterior pituitary gland in the brain. It consists of 191 amino acids. Its primary indication is for children who experience growth failure due to insufficient endogenous growth. Growth Hormone significantly influences skeletal growth, carbohydrate metabolism, lipid metabolism, mineral metabolism, and connective tissue metabolism. The main roles of growth hormone include promoting tissue repair, facilitating cell regeneration in bones, and aiding the immune system in fighting infections and diseases.

 

Qomatropin is indicated for conditions such as growth failure; Turner Syndrome; Somatropin Deficiency Syndrome; Small for Gestational Age (SGA); Idiopathic Short Stature; Prader-Willi Syndrome; and adults with AIDS-related wasting.

 

Before administration, the lyophilized Somatropin powder should be gradually dissolved with 1ml of sterile water for injection or bacteriostatic water for injection.

 

The recommended dosage for Qomatropin is 0.1 IU/kg body weight once daily, typically administered in the evening prior to sleep, preferably in the abdominal region. The injection site should be rotated frequently to avoid lipoatrophy.

 

Contraindications include patients with closed epiphysis, evidence of tumor activity or active neoplasia (intracranial lesions must be quiescent and antitumor therapy completed before starting treatment). Qomatropin should be discontinued if any signs of tumor activity arise. Additionally, individuals allergic to any component of the product are advised against its use.

 

There is limited clinical experience regarding the safety of Qomatropin in individuals older than 60 years.

 

A small number of children treated with Qomatropin have developed leukemia, although a direct connection has yet to be established.

 

Approximately 2% of patients may develop antibodies. Among 232 patients receiving Qomatropin for 6 months, 4.7% showed serum binding of radiolabeled growth hormone exceeding twice that seen in control sera.

 

Qomatropin may lead to side effects such as headaches, localized muscle pain, arthralgia, carpal tunnel syndrome, weakness, mild hyperglycemia, and glucosuria. Mild transient edema occurs in 2.5% of patients early in treatment, and local urticarial reactions have been infrequently reported at the injection site.